OSE Immunotherapeutics SA, a clinical-stage biotechnology company developing first-in-class therapies in immuno-oncology and immuno-inflammation, announced today changes within its leadership team.
Following the confirmation of Marc Le Bozec as CEO on March 10, the company is evolving its Executive Committee by appointing Thomas Gidoin as Deputy CEO and Aurore Morello as Chief Scientific Officer. These appointments reflect OSE’s commitment to implementing its 2026-2028 strategic plan, while continuing to innovate through strong and recognized scientific expertise in immunology.
Marc Le Bozec, CEO, stated: “OSE has entered 2026 with an ambitious new 2026-2028 strategic plan focused on creating value for shareholders. The appointments of Thomas Gidoin as Deputy CEO and Dr. Aurore Morello as Chief Scientific Officer strengthen a united and renewed management team, fully committed to our strategic objectives. I look forward to continuing this collective effort to reveal the full potential of OSE’s assets in the months and years to come.”
Thomas Gidoin, previously Chief Financial Officer, is appointed Deputy CEO in addition to his current role, to support Marc Le Bozec in implementing OSE’s strategic plan. In his new roles as Deputy CEO and CFO, he will oversee the company’s financial strategy, develop investor relations, and supervise communications, as well as legal and corporate affairs.
Aurore Morello, PhD, previously Research Director and R&D Programs Director, is appointed Chief Scientific Officer. In her new role, she will oversee OSE’s research strategy, drive innovation in R&D, and lead the company’s scientific teams in developing monoclonal antibodies, immunocytokines, and RNA-based immunotherapies. Dr. Morello will also lead OSE’s Scientific Council, contributing to the strategic direction of the company’s scientific roadmap.
Aurore Morello holds a doctorate in immunology and oncology from the University of Bordeaux, and completed a postdoctoral fellowship at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, focusing on CAR-T cell therapies for solid tumors. She is the author of numerous publications in leading scientific journals and has received several awards, including the MSKCC Young Researcher Award. Dr. Morello joined OSE Immunotherapeutics in 2016.
